Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients

Pediatric Blood and Cancer

Volumn 48, Issue 5, 2007, Pages 504-509

  Strenger, Volker ^a   Kerbl, Reinhold ^a   Dornbusch, Hans Jürgen ^a   Ladenstein, Ruth ^b   Ambros, Peter F ^b   Ambros, Inge M ^b   Urban, Christian ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Dopamine; Homovanillic acid; Neuroblastoma; Urinary catecholamines; Vanillylmandelic acid

Indexed keywords

CATECHOLAMINE; DOPAMINE; HOMOVANILLIC ACID; VANILMANDELIC ACID;

ARTICLE; CANCER STAGING; CANCER SURGERY; CATECHOLAMINE URINE LEVEL; CLINICAL FEATURE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

ADOLESCENT; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; DOPAMINE; FEMALE; HOMOVANILLIC ACID; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VANILMANDELIC ACID;

EID: 33947688279     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20888     Document Type: Article

References (32)

1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
2. Nishi M, Miyake H, Takeda T, et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987;60:433-436.
3. Sawada T, Hirayama M, Nakata T, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;2:271-273.
4. Murphy SB, Cohn SL, Craft AW, et al. Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet 1991;337:344-346.
5. Nakagawara A, Zaizen Y, Ikeda K, et al. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 1991; 68:2037-2044.
6. Kerbl R, Urban CE, Ladenstein R, et al. Neuroblastoma screening in infants postponed after the sixth month of age: A trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features. Med Pediatr Oncol 1997;29:1-10.
7. Kerbl R, Urban CE, Ambros PF, et al. Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115000 screened infants in Austria. Eur J Cancer 1996; 32A:2298-2305.
8. Brodeur GM, Look AT, Shimada H, et al. Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncol 2001;36:157-159.
9. Schilling FH, Berthold F, Erttmann R, et al. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: Interim results. Med Pediatr Oncol 2000;35:701-704.
10. Barontini M, Gutierrez MI, Levin G, et al. N-myc oncogene and urinary catecholamines in children with neuroblastoma. Med Pediatr Oncol 1993;21:499-504.
11. Izbicki T, Bozek J, Perek D, et al. Urinary dopamine/noradrenaline and dopamine/vanillylmandelic acid ratios as a reflection of different biology of adrenergic clones in children's neuroblastic tumors. Pediatr Surg 1991;26:1230-1234.
12. Nakagawara A, Ikeda K, Higashi K, et al. Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery 1990;107:43-49.
13. Nakagawara A, Ikeda K, Tasaka H. Dopaminergic neuroblastoma as a poor prognostic subgroup. J Pediatr Surg 1988;23:346-349.
14. Laug WE, Siegel SE, Shaw KN, et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77-83.
15. O'Meara A, Tormey W, FitzGerald RJ, et al. Interpretation of random urinary catecholamines and their metabolites in neuroblastoma. Acta Paediatr 1994;83:88-92.
16. Zambrano E, Reyes-Mugica M. Hormonal activity may predict aggressive behavior in neuroblastoma. Pediatr Dev Pathol 2002;5: 190-191.
17. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-2103.
18. Ambros PF, Ambros IM, Strehl S, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer 1995;31A:510-515.
19. Ambros PF, Ambros IM. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001;37:492-504.
20. Ambros PF, Ambros IM, Kerbl R, et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001;36:1-4
21. Yamamoto K, Hanada R, Kikchi A, et al. Spontaneous regression of neuroblastoma detected by mass screening. J Clin Oncol 1998;16: 1265-1269.
22. Yoneda A, Oue T, Imura K, et al. Observation of untreated patients with neuroblastoma detected by mass screening: A "wait and see" pilot study. Med Pediatr Oncol 2001;36:160-162.
23. Fritsch P, Kerbl R, Lackne r H, et al. "Wait and see" strategy in localized neuroblastoma in infants: An option not only for cases detected by mass screening. Pediatr Blood Cancer 2004;43:679-682.
24. Fauler G, Leis HJ, Huber E, et al. Determination of homovanillic acid and vanillylmandelic acid in neuroblastoma screening by stable isotope dilution GC-MS. J Mass Spectrom 1997;32:507-514.
25. Ladenstein R, Urban C, Gadner H, et al. First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study. Eur J Cancer 1995;31A:637-641.
26. Favrot MC, Ambros P, Schilling F, et al. Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Proposal for a common methodology of analysis. SENSE group. Ann Oncol 1996;7:607-611.
27. Strehl S, Ambros PF. Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. Cytogenet Cell Genet 1993;63:24-28.
28. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-363.
29. Joshi VV. Peripheral neuroblastic tumors: Pathologic classification based on recommendations of international neuroblastoma pathology committee (modification of shimada classification). Pediatr Dev Pathol 2000;3:184-199.
30. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 2001;92:2451-2461.
31. Kerbl R, Ambros IM, Ambros PF, et al. Neuroblastoma with focal MYCN amplification and bone marrow infiltration: A staging and treatment dilemma. Med Pediatr Oncol 2002;38:109-111.
32. Mehes G, Luegmayr A, Kornmuller R, et al. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol 2003;163(2):393-399.